Novo Nordisk’s Mim8 shows promising efficacy and safety in haemophilia A children, phase 3 interim results reveal

Novo Nordisk A/S has announced encouraging interim results from its phase 3 FRONTIER3 clinical trial, highlighting the potential of its investigational drug, Mim8, as a ... Read More